Letters Guidance on collaboration with drug industry

An alternative set of principles for consideration

BMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e2927 (Published 24 April 2012) Cite this as: BMJ 2012;344:e2927
  1. Tom A Yates, MRC advanced course master’s student in epidemiology1,
  2. Carl J Reynolds, core trainee year 1 in acute medicine2
  1. 1London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
  2. 2Chelsea and Westminster Hospital, London, UK
  1. thomas.yates{at}lshtm.ac.uk

It is disappointing to see so many reputable organisations join the Association of the British Pharmaceutical Industry (ABPI) in endorsing such a damaging and ill conceived document.1 2 Unreferenced statements such as “Healthcare and industry professionals are able to manage their relationships with each other without compromising clinical decision making,”2 at odds with a growing body of evidence,3 are unhelpful.

We would …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe